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Background: Thrombospondin (TSP) is a multi-functional protein that appears to have dual roles in cancer, that is,
either as a promoter or a suppressor. 4N1K is a TSP-derived peptide that has been reported to be associated with
neovascularity, cell survival, and invasion. There is a little information regarding its pathological roles in human
cancer tissues. Our aim was to clarify clinical significance and prognostic value of 4N1K expression in patients with
urothelial carcinoma of the upper urinary tract (UC-UUT).
Methods: We investigated 4N1K expression in 97 surgically excised, non-metastasized UC-UUT specimens and five
normal tissues via immunohistochemistry. Microvessel density (MVD), lymph vessel density (LVD), cancer cell
proliferation (PI), apoptotic index (AI), and matrix metalloproteinase (MMP)-9 expression was also determined. The
relationships 4N1K expression and pT stage, grade, and prognosis were analysed. In addition, correlations with
these cancer-related and TSP-related factors were also investigated.
Results: Strong and moderate 4N1K expression was found in normal urothelial tissues. Of the 97 specimens, 45
patients were positive for 4N1K expression, which was primarily located in the interstitial areas of the cancer tissue.
4N1K expression was negatively associated with pT stage (p= 0.003) and grade (p= 0.002). Survival analyses
revealed that 4N1K is a predictor of metastasis-free (p= 0.036) and cause-specific survival (p= 0.009). 4N1K
expression was closely associated with malignant behaviour, specifically MVD (p= 0.001), AI (p= 0.013), and MMP-9
expression (p= 0.036), but not PI and LVD, as determined via multivariate analysis models.
Conclusions: 4N1K expression appears to be associated with cancer cell progression and survival in UC-UUT
patients via the regulation of angiogenesis, apoptosis, and MMP-9 expression. There is a possibility that the
4N1K-peptide may be a useful marker and novel therapeutic target in patients with UC-UUT.
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Urothelial cancer (UC) of the upper urinary tract (UUT)
is relatively rare, and accounts for only 5% of all UC;
however, its prognosis is very poor. For example, the
5-year survival rate of patients with pT4 or metastasis
is only 10% [1]. To improve survival and morbidity,
numerous reports on the biological and pathological
characteristics of this type of cancer have been* Correspondence: int.doc.miya@m3.dion.ne.jp
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reproduction in any medium, provided the orpublished [2]. However, more detailed and accurate in-
formation regarding its pathological features, biological
markers for outcome, and potential therapeutic targets
is warranted to improve follow-up and develop treat-
ment strategies for patients with UC-UUT.
Angiogenesis plays a key role in various physiological
and pathological processes [3]. Additionally, angiogenesis
is important in tumour growth, metastasis, and prognosis
in many types of malignancies, including UC [3,4].
Thrombospondin (TSP)-1 is a well-known potent inhi-
bitor of angiogenesis in various physiological andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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eration, migration, and formation of tube-like structures
in endothelial cells [5,6]. These anti-angiogenic functions
of TSP-1 are also present in various cancers [7]. Con-
versely, it is thought that TSP-1 can also stimulate angio-
genesis in cancer [8]. Indeed, the pro-angiogenic effects of
TSP-1 have been previously detected in several cancers in-
cluding pancreatic cancer and gastric cancer [9,10]. Thus,
TSP-1 has opposing angiogenic functions that are
dependent on the cancer type.
In recent years, many investigators have paid attention
to lymph angiogenesis, as it has been proposed to play
important roles in the dissemination of cancer cells and
progression of various cancers similar to angiogenesis
[11,12]. Several reports demonstrated that TSP-1 is sig-
nificantly associated with vascular endothelial growth
factor (VEGF) function in various cancers [10,13,14].
Furthermore, VEGF was also reported to be associated
with lymph angiogenesis in cancer tissues, including UC
[3]. Thus, while there is a possibility that TSP-1 is asso-
ciated with lymph angiogenesis in patients with cancer,
there is no information regarding this issue in human
cancer tissues.
TSP-1 can also regulate the production of matrix
metalloproteinase (MMP)-9 [15,16]. MMP-9 is a type IV
collagenase of the MMP family that is capable of cleav-
ing a wide range of extracellular matrix components
[17]. In fact, increased MMP-9 levels have been reported
to be closely associated with high stages of cancer in
various human tissues, including UC-UUT [16,18].
However, as with angiogenesis, TSP-1 appears to have
dual roles in the regulation of MMP-9 function in can-
cer, that is, either as a stimulator [13,15] or an inhibitor
[19,20]. In regards to TSP-1 and tumour growth, there
are several reports suggesting that TSP-1 may inhibit
cancer cell proliferation in several cancers [21,22]. Des-
pite this, TSP-1 was also previously reported to stimulate
cell proliferation in colon cancer cells [23]. Thus, TSP-1
is capable of acting as both a stimulator and inhibitor of
cancer cell proliferation. It is well-known that TSP-1 can
induce apoptosis in endothelial cells [7]. Similarly, sev-
eral investigators have found that TSP-1 induces apop-
tosis in malignant cells [24,25]. However, other
investigators reported that TSP-1 has anti-apoptotic
effects in thyroid cancer [26]. Thus, the direct function
and pathological role of TSP-1 in regards to apoptosis of
cancer cells is not still fully understood.
There is a wide range of opinions regarding the patho-
logical role, clinical significance, and predictive value of
TSP-1 in cancer patients. For example, there are several
reports suggesting that low TSP-1 expression is corre-
lated with increases in malignant aggressiveness and
poorer outcomes in several cancers, including bladder
cancer, prostate cancer, and renal cell carcinoma[14,22,27,28]. Furthermore, high expression of TSP-1
has been associated with high grade, high stage, and
poor prognosis in several cancers [13,29,30]. On the
other hand, TSP-1 expression has not been associated
with the clinicopathological features of renal cell carcin-
oma and advanced gastric cancer [10,31]. Consequently,
the roles of TSP-1 in the clinicopathological features,
malignant aggressiveness, and prognosis of various
cancers are extremely confusing. Further studies are
necessary to reach a consensus on the pathological sig-
nificance of TSP-1 in various cancers.
TSP-1 is a disulfide-bonded trimer with several differ-
ent domains. Specifically, it consists of an N-terminal
domain, a pro-collagen homology region, CSVTCG
sequences within the type I repeats, a RGD sequence
within the type 3 repeats, and a C-terminal domain [32].
As mentioned previously, the regulation of TSP-1 func-
tion is complex, and involves direct and indirect effects.
To clarify the detailed biological and pathological func-
tions of TSP-1, various synthetic peptides derived from
TSP-1, such as peptide from the type I repeats (i.e.
KRFK and WSHSPW) and peptides from the N-terminal
domain (i.e. GQGVLQNVRFVF), have been used
[33,34]. Interestingly, one report suggests that the 4N1K
peptide (KRFYVVMWKK), which is derived from the C-
terminal domain of TSP-1, inhibits angiogenesis both in
in vivo and in vitro models [35]. 4N1K expression was
also reported to be negatively associated with angiogen-
esis in human renal cell carcinoma tissues [31]. How-
ever, the clinical and pathological significance of the
4N1K peptide in urothelial cancer (UC) is still unknown.
In the present study, we paid close attention to the
pathological role, clinical significance, and prognostic
value of 4N1K expression in patients with UC of the
upper urinary tract (UC-UUT), as this cancer is charac-
terized by frequent recurrence after initial treatment.
Angiogenesis, lymph-angiogenesis, proliferation, apop-
tosis, and MMP-9 are known to affect the malignant be-
haviour, tumour progression, and prognosis of UC-UUT
[16,18]. Thus, the main goal of the present study was to
examine whether 4N1K expression correlates with ma-
lignant behaviour, clinicopathological features, and prog-
nosis in patients with non-metastatic UC-UUT.
Methods
Patients
Ninety-seven consecutive patients, who were diagnosed
with non-metastatic UC-UUT, were reviewed retrospect-
ively. This study included 72 men and 25 women, ranging
in age from 39 to 87 years (median age: 67 years). Patients
that received any preoperative therapy were excluded. All
histological diagnoses, including tumour grade and pT
stage, were determined from formalin-fixed and paraffin-
embedded specimens obtained from the radical operation.
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node-metastasis (TNM) classification, and cancer grade
was divided into three grades (i.e. G1, G2, and G3),
according to World Health Organization (WHO) classifi-
cation and other recent reports on UC-UUT [36,37]. A
single pathologist performed all of the pathological exam-
inations, including lymph and/or blood vessel vascular
invasion (LVI), which are assessed by regular
hematoxylin and eosin staining. The median follow-up
period was 44 months (range: 3–250 months). Fifteen
(15.4%) patients experienced metastasis after surgery. In
addition, 11 patients had local and/or bladder metastasis
after recurrence. Seventy-three (75.3%) patients were
alive at the last follow-up examination, while 24
patients (24.7%) had died due to TCC-related disease.
The study protocol was approved by the Human Ethics
Review Committee of the Nagasaki University Hospital.
Immunohistochemistry
The methodology for immunohistochemical staining and
terminal deoxynucleotidyl transferase-mediated nick and
labelling (TUNEL) was previously described elsewhere
[11,31]. Briefly, 5-μm-thick sections were deparaffinized
in xylene and rehydrated in ethanol. Antigen retrieval
was performed for all immunohistochemical staining. All
sections were then immersed in hydrogen peroxide to
block endogenous peroxidase activity. The primary anti-
body for 4N1K-containing peptide was previously used
by our group, and its specificity was confirmed in several
other reports [31,35]. The other antibodies used were
obtained from commercial companies. They were as fol-
lows: anti-Ki-67 and anti-D2-40 (Dako Corp., Glostrup,
Denmark), anti-CD31 (Novocastra, Newcastle, United
Kingdom), anti-MMP-9 (Daiichi Fine Chemical, Toyama,
Japan), and anti-cleaved caspase-3 (R & D systems, Inc.,
Abingdon, United Kingdom). Sections were incubated
with the primary antibody at 4 °C overnight. After in-
cubation with the primary antibody, the sections were
washed extensively, and then treated with peroxidase
using the labelled polymer method with DAKO
EnVision + TM Peroxidase (Dako Corp., Carpinteria,
CA). The peroxidase reaction was visualized with the
liquid DAB substrate kit (Zymed Laboratories Inc., San
Francisco, CA). Sections were counterstained with
hematoxylin, dehydrated stepwise through a graded al-
cohol series, and cleared in xylene before mounting. A
consecutive section from each sample processed with-
out the primary antibody was used as a negative con-
trol. Positive controls were similar to those used in
previous reports. To evaluate the apoptotic cells, we
determined two parameters, the proportions of cleaved
caspase-3- and TUNEL-positive cells. The method of
in situ labelling for apoptosis was performed as previ-
ously described [38]. We used the Apop Tag In SituApoptosis Detection Kit (Intergen Company, Purchase,
NY), which is based on TUNEL.
Immunohistochemical staining was assessed with light
microscopy, where staining intensity was graded as none,
weak, moderate, or strong. Carcinoma cells that demon-
strated moderate or strong staining were considered to
be positively stained cells. The evaluations of immuno-
histochemical staining for Ki-67, CD31, and MMP-9
were performed as previously described [18,38]. For all
variables, values above the median were considered as
the higher group, and those with staining equal to or less
than the median value were considered as the lower
group for statistical analyses, including logistic regression
analyses. Immunoreactive staining was evaluated using
the semi-quantification method. To ensure accuracy and
validity, slides were blindly evaluated twice at different
times by two investigators (Y.M. and S.W.). All speci-
mens were examined using a Nikon E-400 microscope
and digital images were captured (Nikon DU100, Tokyo,
Japan). Additionally, we used a computer-aided image
analysis system (Win ROOF, version 5.0, MITANI, Fukui,
Japan) to calculate the statistical variables.
Statistical analyses
Normality was evaluated via a normal distribution and
histograms for each variable. Data are expressed as med-
ians (interquartile range), unless otherwise stated. The
Mann–Whitney U test was performed for continuous
variables, and the chi-square test was used for categor-
ical comparison of the data. The crude and adjusted
effects on tumour stage and grade, as well as other risk
factors, were estimated by logistic regression analysis,
and were described as odds ratios (OR) with 95% confi-
dence intervals (95% CI), together with the p values.
Variables that achieved statistical significance in the
univariate analysis were subsequently included into a
multivariate analysis model. The metastasis-free and
cause-specific survival rates were compared with
Kaplan-Meier analysis and a log rank test. Variables that
achieved statistical significance (p < 0.050) in the univari-
ate analysis were subsequently entered into a multivari-
ate analysis using a COX proportional hazards analysis,
and results were described as hazard ratio (HR) with
95% CI and the P values. All statistical tests were two-
sided and significance was defined as p < 0.050. All stat-
istical analyses were performed on a personal computer
with the statistical package, StatView for Windows
(Version 5.0, Abacus Concept, Inc., CA).
Results
4N1K expression
Representative examples of 4N1K expression are pre-
sented in Figure 1. Immunostaining for this peptide was
primarily detected in the intestinal tissues, and, in part,
Figure 1 (A) In normal urothelial cells, strong or moderate
4N1K expression was detected in all specimens. (B) In cancer
tissues, some specimens demonstrated strong or moderate 4N1K
expression. This figure was a representative example of strongly
stained cancer cells (C) A representative image of weakly stained
tissues for 4N1K peptide. All sections were counterstained in
hematoxylin (Magnification: ×400; Bar means 10 μm).
Table 1 Pathological features and 4N1K expression
parameters n 4N1K expression p
valueNegative (%) Positive (%)
pT stage
Ta 7 2 (28.6) 5 (71.4) 0.003
T1 36 13 (36.1) 23 (63.9)
T2 17 7 (41.2) 10 (58.8)
T3 27 21 (77.8) 6 (22.2)
T4 10 8 (80.0) 2 (20.0)
Low (Ta + 1) 43 15 (34.9) 28 (65.1) 0.002
High (T2-4) 54 36 (66.7) 18 (33.3)
Grade
Low grade 55 21 (38.2) 33 (61.8) 0.001
High grade 42 30 (71.4) 12 (28.6)
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cells, including infiltrating, endothelial, and fibroblast-
like cells, showed 4N1K immunostaining. Strong and
moderate expression of the 4N1K peptide was found in
normal urothelial tissues of all 5 specimens (Figure 1A).Representative examples of strong expression judged to
be high, and weak expression judged to be low, are pre-
sented in Figures 1B and C, respectively. Forty-five
patients (47.4%) were judged to have high expression of
the 4N1K peptide. We noticed that this peptide demon-
strated a trend of being strongly expressed near neigh-
bouring stromal tissues, including blood vessels in
cancer tissues. However, clear characteristics regarding
the distribution of 4N1K expression were not evident.
Correlation with clinicopathological features
The correlations between 4N1K expression and patho-
logical features are presented in Table 1. In non-muscle
invasive cancer (NMIBC; pTa + 1), 28 of 43 patients
(65.1%) were judged as positive. Conversely, in muscle
invasive disease, its ratio (18 of 54 patients = 33.3%) was
significantly lower (p= 0.002) compared to NMIBC.
With respect to grade, there was a similar trend, where
4N1K expression negatively correlated with the grade
(p= 0.001). To further determine the function of 4N1K
expression, univariate and multivariate analyses were
performed. Using univariate analyses, it was found that,
with the exception of LVD, all of the other factors were
associated with 4N1K expression (Figure 2A-E). Further-
more, it was found that 4N1K expression independently
correlated with MVD (OR= 4.01; 95% CI = 1.48-10.88;
p= 0.001), AI (OR= 2.39; 95% CI = 1.06 – 5.42;
p= 0.036), and MMP-9 expression (OR= 3.36; 95% CI =
1.30-8.69; p= 0.013), as determined via multivariate ana-
lysis models, which included pT stage and grade.
Correlation with survival
No significant relationship was observed between 4N1K
expression and site of metastasis. Survival analyses
demonstrated that negative expression of 4N1K peptide
is a poor prognostic factor for metastasis-free survival




























































































































Figure 2 Correlations between 4N1K expression and (A) microvessel density (MVD), (B) lymph-vessel density (LVD), (C) cancer cell
proliferation index (PI), (D) apoptotic index (AI), and (E) matrix metalloproteinase-9 expression (MMP-9).
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analyses also revealed that metastasis-free survival and
cause-specific survival were associated with pT stage
(p < 0.001 and p= 0.001) and grade (p= 0.001 and
p= 0.006). Initially, due to our limited sample size, we
used a simple multivariate analysis model, which
included these pathological features. As shown in
Table 2, these analyses revealed that 4N1K expression
was not an independent predictor of metastasis-free sur-
vival and cause-specific survival. On the other hand, in
both analyses, only high pT stage was recognized as an
independent predictor of metastasis-free and cause-
specific survival (Table 2). Additionally, we performed
further multivariate analyses which included the twoformer pathological parameters and adjuvant therapy,
LVI, PI, MVD, and MMP-9 expression since all of these
factors were significantly associated with 4N1K expres-
sion and survival in univariate analyses. These analyses
showed that only high pT stage and presence of LVI
were independent predictors (HR =9.16; 95%CI = 1.02 –
82.58; p= 0.048 and HR= 9.41, 95%CI = 1.91 – 46.42;
p= 0.006) of metastasis-free survival. However, none of
these factors were independent predictors of cause-
specific survival in the multivariate analysis model.
Discussion
Our findings demonstrate that 4N1K peptide expression
in tumour tissues of UC-UUT is negatively associated
0








Log rank P = 0.036
0






































Follow up periods (months)
Follow up periods (months)
A
B
Figure 3 Kaplan-Meier survival curves according to 4N1K
expression status. Patients with negative expression had poorer (A)
metastasis-free (p= 0.036) and (B) cause-specific (p= 0.009) survival
compared to those with positive expression.
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itionally, lower expression levels of this peptide were also
associated with metastasis and survival in patients with
UC-UUT. These observations corroborate those of a
previous report on patients with renal cell carcinoma
[31]. TSP-1 function is affected by the cellular pheno-
type via interactions with various cell surface proteins,
and the status of its microenvironment [7]. For example,
biological activities on cell invasion and focal adhesion
of TSP-1 were depended on its concentration [39].
Moreover, matrix-binding TSP-1 was shown to be influ-
enced by angiogenic function in vitro compared to non-Table 2 Multivariate analysis of metastasis-free and cause-spe
For metastasis-free survival
HR 95% CIs p
pT stage 8.96 1.08 – 74.43
Grade 2.12 0.62 – 7.24
4N1K expression 0.40 0.11 – 1.54
HR; hazard ratio, CIs; confidential intervals.binding TSP-1 [40]. Thus, TSP-1 appears to have a wide
range of the biological functions and pathological roles,
and consequently, TSP-1 protein expression appears to
be an inadequate and unstable marker for the prediction
of pathological features and prognosis in patients with
UC-UUT. Indeed, the pathological role and prognostic
value of TSP-1 expression in patients with UC of the
urinary bladder is controversial. For example, several
reports demonstrated that TSP-1 expression is asso-
ciated with its clinicopathological features, including
grade, pT stage, and lymph node metastasis, as well as
prognosis [14,16]. Conversely, other studies found that
TSP-1 expression is not associated with both the grade
and stage of cancer, but rather with disease progression,
including disease recurrence and overall survival [27,41].
Another report found that TSP-1 expression is asso-
ciated with tumour grade, stage, and size, but not with
disease progression [42]. This study also showed that the
pathological significance of TSP-1 was different in can-
cer cells and stromal tissues.
Synthetic peptides derived from TSP-1 have been used
in previous studies for the investigation of its physio-
logical functions and pathological roles. In the present
study, we focused on the expression of the 4N1K peptide
for the following reasons: i) antibodies against this pep-
tide were shown to block the TSP-1-induced inhibition
of angiogenesis, suggesting that 4N1K plays a crucial
role in the inhibitory effects of TSP-1 on angiogenesis
[35]; and ii) 4N1K expression was found to be closely
associated with malignant potential, cancer cell progres-
sion, and survival in patients with renal cell carcinoma
[31].
Currently, there is no general agreement on the distri-
bution and production of TSP-1 in UC. While some
investigators found TSP-1 expression in tumour stromal
tissues, its expression was weak or absent in bladder
cancer cells [43]. Conversely, other investigators demon-
strated TSP-1 expression in both bladder cancer cells
and tumour stromal tissues [27,42]. Additionally, one re-
port found that TSP-1 expression was detected only
within the cytoplasms of bladder cancer cells [16]. In
bladder cancer cell lines, TSP-1 expression was reported
to be expressed in MGH-U4 and RT-4 cell lines, but not
in RT-112 and UMUC-3 cell lines [44]. Thus, TSP-1 in
UC is thought to be secreted from cancer and/orcific survival
For cause-specific survival
value HR 95% CI p value
0.042 3.14 1.08 – 9.19 0.036
0.230 1.75 0.68 – 4.50 0.036
0.186 0.70 0.27 – 1.81 0.463
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lated that some factors, including a variety of proteases
within interstitial tissues, may break down the 4N1K
peptide in human UC-UUT tissues.
One of the most interesting findings of the present
study is that 4N1K expression is closely associated with
MVD, cancer cell apoptosis, and MMP-9 expression, as
determined via multivariate analyses. With respect to
the relationship between TSP-1 and angiogenesis, several
studies have previously demonstrated that its expression
was significantly associated with MVD in human cancer
tissues, including bladder cancer [10,22,41]. Moreover,
there are a few reports on the relationship between
4N1K peptide and MVD in human cancer tissues. One
report found that the 4N1K protein is capable of inhibit-
ing tube formation in vitro, as well as angiogenesis in
mouse cornea [35]. Additionally, in renal cell carcinoma,
4N1K expression was found to be associated with angio-
genesis. These observations corroborate our finding that
the 4N1K peptide is closely associated with the regula-
tion of angiogenesis in patients with UC-UUT. Despite
this, we also found that 4N1K expression was not asso-
ciated with lymph angiogenesis. This is the first ever
study to report on the relationship between 4N1K ex-
pression and LVD in human cancer tissues. Interestingly,
similar findings were demonstrated with TSP-1. Specific-
ally, it was found that increases in the expression of
TSP-1 inhibited angiogenesis, but did not affect lymph
angiogenesis in mice [45].
There is little information available regarding the rela-
tionship between 4N1K peptide expression and cancer
cell apoptosis in human cancer tissues. It has been sug-
gested that CD47/integrin-associated protein (IAP)-
binding protein play an important role in the apoptosis
of various cells [7,46]. The 4N1K peptide has also been
shown to induce apoptosis-like cell death in immune
cells [47]. Furthermore, 4N1K expression was previously
shown to be positively associated with AI in human
renal cell carcinoma tissues [31]. These findings support
our observations, specifically that the 4N1K peptide
may have pro-apoptotic functions in patients with UC-
UUT. However, another peptide, 4 N1 (RFYVVMWK),
which is also derived from the CD47/IAP-binding
domain and has a similar structure to the 4N1K peptide
(KRFYVVMWKK), has been shown to inhibit apoptosis
of human thyroid cancer cells [26]. Thus, further stud-
ies are necessary, as the biological activities of these
peptides appear to be dependent on the cell type and
situation.
Another interesting finding of the present study was
that a negative expression of 4N1K peptide was signifi-
cantly and closely associated with an elevated expression
of MMP-9, as determined via multivariate analysis. The
regulation of MMP-9 expression and function throughTSP-1 is very complex. For example, a low dose of TSP-
1 stimulates its expression, whereas a high dose TSP-1
inhibits its expression [48]. Additionally, certain peptides
derived from TSP-1, such as type I repeats [19] and
CSVTCG sequence [13], are known to bind to MMP-9
and inhibit its activation. In regards to the role of TSP-1
in regulating MMP-9 in cancer cells, there were several
opinions that TSP-1 acts as an inhibitor in breast cancer
[19] and ovarian cancer [20]. In UC, TSP-1 expression
was found to be negatively correlated with MMP-9 ex-
pression [16]. Although there are no reports on the
effects of 4N1K on MMP-9 expression in human cancer
patients, these findings support our observation. How-
ever, there is one report that found that the 4N1K pep-
tide up-regulates MMP-9 in neurovascular cells [49].
Thus, more detailed studies are necessary to determine
the pathological function of the 4N1K peptide in the
regulation of MMP-9 expression in UC.
Our study has the limited sample size and variables
were evaluated by semi-quantification. So, further inves-
tigations are necessary to clarify the biological activities
and pathological function of 4N1K peptide in UC-UUT.
However, our results were important information to dis-
cuss the clinical significance of 4N1K peptide expression
in these patients.
Conclusions
Our results showed that 4N1K expression was negatively
associated with malignant potential and tumour growth
in patients with UC-UUT. In addition, patients with a
negative expression of 4N1K had a poorer prognosis for
metastasis and cause-specific survival. We speculated
that 4N1K expression may affect to these malignant be-
haviour and prognosis via regulation of angiogenesis,
apoptosis, and MMP-9 expression. Additionally, our
observations are also useful for discussing follow-up and
treatment strategies in patients with UC-UUT.
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